Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

GLUE vs RGNX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

GLUE Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 6–4 Matrix Metrics)

GLUE Overall Winner 6-Pillar Tally: GLUE 3 – 3 RGNX Matrix Metrics: GLUE 6 – 4 RGNX

As of Nov 16, 2026, Monte Rosa Therapeutics, Inc. (GLUE) is the stronger overall head-to-head candidate over REGENXBIO Inc. (RGNX) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). GLUE carries a Unified Composite Score of 44.2/100 (HOLD) at $9.18 (10.0x Forward P/E, -214.5% operating margin), whereas RGNX carries 45.3/100 (HOLD) at $7.45 (N/M Forward P/E, -120.4% operating margin).

  • Composite vs. Pillar Nuance: While RGNX currently prints a higher short-term Unified Composite Score (45.3/100 HOLD vs. GLUE 44.2/100 HOLD), GLUE captures the overall institutional head-to-head verdict (6–4 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (-214.5% vs. -120.4% operating margin) and revenue trajectory (+325.8% vs. -69.2% YoY).
  • Technical & Structure Timing Caution: GLUE is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.3); meanwhile RGNX is in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 48.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About GLUE vs RGNX
GLUE NASDAQ Head-to-Head Winner
Monte Rosa Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$9.18
-2.03% 1D
Market Cap $795.5M
TTM Revenue $70M
Forward P/E 10.0x
Beta / 30D Vol 0.95β · 53% Vol
Unified Composite Score
44.2 / 100 HOLD
Tech 32.0 Fund 51.0 Flow 70.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -13.2%), weak momentum, RSI 31
RSI-14: 31.3 · SMA20: $10.50 · SMA50: $11.21
RGNX NASDAQ
REGENXBIO Inc.
Biological Products, (No Disgnostic Substances)
$7.45
-2.49% 1D
Market Cap $500.9M
TTM Revenue $154M
Forward P/E N/M
Beta / 30D Vol 1.82β · 76% Vol
Unified Composite Score
45.3 / 100 HOLD
Tech 36.0 Fund 44.0 Flow 69.0 Mom 50.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -12.2%) with fading momentum, RSI 48
RSI-14: 48.3 · SMA20: $7.42 · SMA50: $7.63

6-Pillar Scorecard Institutional Category Breakdown (GLUE 3 – 3 RGNX)

Columns: Metric · GLUE · RGNX
1. Valuation Multiples GLUE
Forward P/E 10.0x N/M
Trailing P/E 10.0x N/M
PEG Ratio N/M 0.26x
EV / Revenue 11.2x 3.1x
2. Growth & Scale GLUE
Revenue Growth (YoY) +325.8% -69.2%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $70M $154M
Market Cap $795.5M $500.9M
3. Profitability & Quality RGNX
Gross Margin -92.2% -64.5%
Operating Margin -214.5% -120.4%
Net Profit Margin -186.2% -113.9%
Return on Equity (ROE) -35.3% -113.2%
4. Balance Sheet & Cash Flow RGNX
Cash Generation (TTM) -$174M -$155M
Cash Flow Margin N/A -100.6%
Net Cash / Leverage $8.9M Net Cash $29M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning GLUE
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 100.8% (16th %ile) 349.6% (52nd %ile)
Put/Call OI Skew 6.27x (Put-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Markdown ACCUMULATION · Distribution
6. R&D & Supply-Chain Moat RGNX
OpEx & R&D Intensity N/A 55.9% of Rev ($86M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: GLUE (6) vs RGNX (4)
Institutional Metric GLUE RGNX Criterion Row Edge
Market Capitalization
Scale
$795.5M $500.9M Larger Scale GLUE
Trailing P/E Ratio
Valuation
10.0x N/M Lower Multiple GLUE
Forward P/E Ratio
Valuation
10.0x N/M Lower Multiple GLUE
Revenue Growth (YoY)
Growth
+325.8% -69.2% Higher Growth GLUE
Operating Margin (TTM)
Profitability
-214.5% -120.4% Higher Margin RGNX
Net Profit Margin
Profitability
-186.2% -113.9% Higher Margin RGNX
Return on Equity (ROE)
Capital Efficiency
-35.3% -113.2% Higher ROE GLUE
52-Week Range Position
Momentum
1% ($9–$26) 19% ($5–$16) Stronger Trend RGNX
Beta / 30D Volatility
Risk Regime
0.95β · 53% Vol 1.82β · 76% Vol Lower Realized Risk GLUE
Unified Institutional Score
Composite Signal
44.2 / 100 (HOLD) 45.3 / 100 (HOLD) Higher Composite RGNX
Trailing 12M Revenue (USD)
Operating Scale
$70M $154M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
-92.2% -64.5% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 11.2x EV/Rev 0.26x PEG · 3.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$174M ($8.9M Net Cash) -$155M ($29M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon RGNX +13.33 pp
GLUE: -5.75% · RGNX: +7.58%
3M Horizon RGNX +6.22 pp
GLUE: -38.92% · RGNX: -32.7%
6M Horizon RGNX +80.89 pp
GLUE: -49.03% · RGNX: +31.86%
1Y Horizon GLUE +0.11 pp
GLUE: -35.89% · RGNX: -36.0%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period GLUE Revenue RGNX Revenue GLUE Op. Margin RGNX Op. Margin Margin Leader
FY2018 N/A $220M N/A 40.3% RGNX
FY2019 N/A $40M N/A -422.9% RGNX
FY2020 N/A $150M N/A -77.1% RGNX
FY2021 N/A $470M N/A 34.0% RGNX
FY2022 N/A $110M N/A -233.2% RGNX
FY2023 N/A $90M N/A -297.1% RGNX
FY2024 $80M $80M -107.3% -280.0% GLUE
FY2025 $120M $170M -43.8% -94.6% GLUE

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
GLUE BREAKDOWN
85d in phase · OBV DISTRIBUTION
Current IV 100.8%
IV Percentile 16th %ile
Put/Call OI Skew 6.27x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact GLUE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
RGNX BREAKDOWN
91d in phase · OBV ACCUMULATION
Current IV 349.6%
IV Percentile 52nd %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact RGNX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
GLUE Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $795.5M market capitalization and -214.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
RGNX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $500.9M market capitalization and -120.4% operating margin.
OpEx & R&D Reinvestment 55.9% of Rev ($86M)
90D Engineering Disclosures 0 Published

Investor FAQ GLUE vs RGNX Key Questions & Quantitative Answers

As of Nov 16, 2026, Monte Rosa Therapeutics, Inc. (GLUE) is the stronger overall head-to-head candidate over REGENXBIO Inc. (RGNX) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). GLUE carries a Unified Composite Score of 44.2/100 (HOLD) at $9.18 (10.0x Forward P/E, -214.5% operating margin), whereas RGNX carries 45.3/100 (HOLD) at $7.45 (N/M Forward P/E, -120.4% operating margin). Composite vs. Pillar Nuance: While RGNX currently prints a higher short-term Unified Composite Score (45.3/100 HOLD vs. GLUE 44.2/100 HOLD), GLUE captures the overall institutional head-to-head verdict (6–4 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (-214.5% vs. -120.4% operating margin) and revenue trajectory (+325.8% vs. -69.2% YoY). Technical & Structure Timing Caution: GLUE is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.3); meanwhile RGNX is in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 48.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

GLUE leads the Growth & Scale pillar: GLUE posts +325.8% YoY revenue growth and +0.0% YoY earnings growth on $70M TTM revenue (-92.2% gross margin, -214.5% operating margin), compared with RGNX at -69.2% YoY revenue growth and +0.0% YoY earnings growth on $154M TTM revenue (-64.5% gross margin, -120.4% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), GLUE cumulative revenue shifted +50.0% while RGNX shifted -22.7%. In operating R&D and SG&A reinvestment, GLUE deploys N/A (0 90-day corporate R&D disclosures) versus 55.9% of Rev ($86M) (0 disclosures) for RGNX.

GLUE screens cheaper on headline valuation multiples. GLUE trades at 10.0x Forward P/E, 10.0x Trailing P/E, N/M PEG, and 11.2x EV/Revenue (unreported FCF margin), whereas RGNX trades at N/M Forward P/E, N/M Trailing P/E, 0.26x PEG, and 3.1x EV/Revenue (-100.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against GLUE (-35.3% ROE) versus RGNX (-113.2% ROE) capital efficiency.

In options market volatility and institutional positioning, GLUE carries 100.8% implied volatility (16th %ile, Compressed (<25th %ile)), a 6.27x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.95β · 53% Vol realized risk). By comparison, RGNX carries 349.6% implied volatility (52nd %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.82β · 76% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.